Researchers have identified a specific protein in the gut that plays a key role in combating the spread of bacteria. This discovery could lead to potential treatments for conditions like inflammatory bowel disease.
The protein, known as intelectin-2, has been recognised by scientists, but its specific function within the gastrointestinal (GI) tract was previously unclear. Intelectin-2 is classified as a lectin, a type of protein that binds to particular sugar molecules.
A team from the Massachusetts Institute of Technology (MIT) has revealed that intelectin-2 operates in two ways. Firstly, it connects mucus molecules that line the GI tract, enhancing the protective mucus barrier around intestinal tissues. Secondly, if the barrier is breached, intelectin-2 identifies and traps various bacterial cells, either inhibiting their growth or killing them outright.
This dual action of intelectin-2 serves both defensive and offensive purposes for maintaining health. Researchers employed multiple methods to examine the protein’s activity, including studies on mouse tissue, gut bacteria from both mice and humans, and the human and mouse versions of the protein in a laboratory setting.
Notably, intelectin-2 targets galactose, a simple sugar present in mucus and on the surface of some bacterial cells associated with GI infections. When intelectin-2 binds to and traps these bacteria, they appear to deteriorate over time, presumably due to damage to their outer membranes.
Importantly, some bacteria that intelectin-2 neutralises are resistant to antibiotics, which enhances the significance of this research for drug development.
The scientists believe that intelectin-2’s abilities could lead to innovative treatments, either by developing drugs that mimic its actions or by enhancing its functions within the body. Their findings were published in Nature Communications.
Test Your Understanding
How much do you know?





